Skip to main content

Generic ActoPlus Met Availability

Last updated on Mar 9, 2023.

ActoPlus Met is a brand name of metformin/pioglitazone, approved by the FDA in the following formulation(s):

ACTOPLUS MET (metformin hydrochloride; pioglitazone hydrochloride - tablet;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: August 29, 2005
    Strength(s): 500MG;EQ 15MG BASE (discontinued) [RLD], 850MG;EQ 15MG BASE [RLD] [AB]

Has a generic version of ActoPlus Met been approved?

A generic version of ActoPlus Met has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to ActoPlus Met and have been approved by the FDA:

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; pioglitazone hydrochloride tablet;oral)

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: February 13, 2013
    Strength(s): 850MG;EQ 15MG BASE [AB]
  • Manufacturer: MACLEODS PHARMS LTD
    Approval date: November 5, 2015
    Strength(s): 850MG;EQ 15MG BASE [AB]
  • Manufacturer: TEVA PHARMS USA
    Approval date: March 10, 2014
    Strength(s): 850MG;EQ 15MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Solid preparation
    Patent 9,101,660
    Issued: August 11, 2015
    Assignee(s): Takeda Pharmaceutical Company

    The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like, and which is superior in preparation characteristics such as content uniformity and dissolution property of the insulin sensitizer and the active ingredient (except insulin sensitizers), preparation hardness and the like.

    Patent expiration dates:

    • January 22, 2027
      Drug product
  • Tablet
    Patent 9,320,714
    Issued: April 26, 2016

    The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the yield. The tablet is a tablet (1) longer in one direction when seen in plan. The tablet (1) has side edges (6) each of which extends in a longitudinal direction and is formed in the shape of a curve projecting outwardly in plan view. The curve has a radius of curvature (R1) set to at least 1.5 times a length (L) of the tablet. This makes a projected area of the tablet (1) in plan view at least 97% with respect to a projected area of a standard elliptical tablet having opposite end portions each of which is formed by a semi-circle having a diameter of a width (W) of the tablet.

    Patent expiration dates:

    • February 3, 2029
      Drug product


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.